These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15477366)

  • 1. Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen.
    Coviello AD; Bremner WJ; Matsumoto AM; Herbst KL; Amory JK; Anawalt BD; Yan X; Brown TR; Wright WW; Zirkin BR; Jarow JP
    J Androl; 2004; 25(6):931-8. PubMed ID: 15477366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reinitiation of sperm production in gonadotropin-suppressed normal men by administration of follicle-stimulating hormone.
    Matsumoto AM; Karpas AE; Paulsen CA; Bremner WJ
    J Clin Invest; 1983 Sep; 72(3):1005-15. PubMed ID: 6411766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial.
    Anawalt BD; Amory JK; Herbst KL; Coviello AD; Page ST; Bremner WJ; Matsumoto AM
    J Androl; 2005; 26(3):405-13. PubMed ID: 15867009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist on spermatogenesis and intratesticular steroid levels in normal men.
    Matthiesson KL; Stanton PG; O'Donnell L; Meachem SJ; Amory JK; Berger R; Bremner WJ; McLachlan RI
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5647-55. PubMed ID: 16030154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist.
    Matthiesson KL; Amory JK; Berger R; Ugoni A; McLachlan RI; Bremner WJ
    J Clin Endocrinol Metab; 2005 Jan; 90(1):91-7. PubMed ID: 15509637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations.
    Anawalt BD; Bebb RA; Bremner WJ; Matsumoto AM
    J Androl; 1999; 20(3):407-14. PubMed ID: 10386821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment.
    McLachlan RI; Robertson DM; Pruysers E; Ugoni A; Matsumoto AM; Anawalt BD; Bremner WJ; Meriggiola C
    J Clin Endocrinol Metab; 2004 Jan; 89(1):142-9. PubMed ID: 14715841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression.
    Coviello AD; Matsumoto AM; Bremner WJ; Herbst KL; Amory JK; Anawalt BD; Sutton PR; Wright WW; Brown TR; Yan X; Zirkin BR; Jarow JP
    J Clin Endocrinol Metab; 2005 May; 90(5):2595-602. PubMed ID: 15713727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily testosterone and gonadotropin levels are similar in azoospermic and nonazoospermic normal men administered weekly testosterone: implications for male contraceptive development.
    Amory JK; Anawalt BD; Bremner WJ; Matsumoto AM
    J Androl; 2001; 22(6):1053-60. PubMed ID: 11700852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA; Wallace AM; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men.
    McLachlan RI; O'Donnell L; Stanton PG; Balourdos G; Frydenberg M; de Kretser DM; Robertson DM
    J Clin Endocrinol Metab; 2002 Feb; 87(2):546-56. PubMed ID: 11836283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.